Phase I
MyoKardia, Inc. announced that it has dosed the first subjects in a Phase 1 clinical study of MYK-224, a small molecule candidate being developed for the treatment of hypertrophic cardiomyopathy.
Forendo Pharma announces initiation of dosing in a Phase 1b clinical study in its lead endometriosis program with the aim to demonstrate Proof of Mechanism.
“It’s important to recognize that this problem is there and this problem is persisting over the years,” Kanwal Raghav, author of the study and an oncologist at MD Anderson Cancer Center, told STAT.
As summer winds its way to an end, biopharmaceutical companies continue to conduct clinical trials and release news related to them. Here’s a look at last week’s clinical trial headlines.
Coordination Pharmaceuticals Inc., a privately-held oncology drug development company announced that the first patient has been dosed in a Phase 1 study of CPI-200 in patients with advanced tumors.
Cytovation AS and Specialized Medical Services-oncology BV announce that SMS-oncology has been selected as the CRO to conduct the phase I/II clinical trial with CyPep-1 in patients with advanced solid cancers.
Last week was a particularly busy week for biopharma companies to release information about ongoing clinical trials. Here’s a look.
Every week brings news of clinical trials, ranging from launches, first-patient dosing, full enrollment, interim data or final data. Here’s a look at some of the clinical trial news from last week.
An experimental vaccine for respiratory syncytial virus (RSV) showed positive results in a Phase I clinical trial. Researchers from The University of Texas at Austin and others reported that a single dose of the vaccine produced significant evidence of RSV-neutralizing antibodies that were sustained for several months.
Amicus Therapeutics announced positive interim results from its CLN6 Batten disease gene therapy program. Batten disease is a fatal neurologic illness that results in children losing the ability to walk, speak, think and see.
PRESS RELEASES